Novo Nordisk LinkedIn - Search News

News

Novo Nordisk shares dip further

Reuters on MSN · 11h

Novo Nordisk shares dip further as Wegovy gains nearly erased

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago.

QuickTake on MSN · 13h

How Novo Nordisk Gave Up Its Weight-Loss Gains

How did Novo lose its edge in the weight-loss market? Novo was a first mover when it comes to so-called GLP-1 treatments, which cause weight loss by mimicking the appetite-control

Hosted on MSN · 16h

Novo Nordisk shares extend losses, erasing nearly all gains since Wegovy launch

(Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday to their lowest since August 2021, extending recent losses to wipe out almost all the gains made since the drugmaker launched its blockbuster weight-loss treatment Wegovy.

2don MSN

Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?

In April, Danish drugmaker Novo Nordisk formed what was supposed to be a long-term collaboration to promote its weight-loss ...

2don MSN

Novo Nordisk slides further on US competition, new CEO concerns

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

2don MSN

Novo CEO’s First Test Is Winning Back the US Weight-Loss Market

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

GlobalData on MSN2d

Novo Nordisk shares plummet as 2025 guidance is cut, overshadowing new CEO

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results